Consolidated Statements of Comprehensive Loss ₪ in Thousands, $ in Thousands |
12 Months Ended | |||
|---|---|---|---|---|
|
Dec. 31, 2017
ILS (₪)
₪ / shares
shares
|
Dec. 31, 2017
USD ($)
$ / shares
shares
|
Dec. 31, 2016
ILS (₪)
₪ / shares
shares
|
Dec. 31, 2015
ILS (₪)
₪ / shares
shares
|
|
| Profit (loss) [Abstract] | ||||
| Revenue | ₪ 1,668 | $ 481 | ₪ 292 | |
| Cost of Revenue | 52 | 15 | ||
| Gross Profit | 1,616 | 466 | 292 | |
| Research and development expenses: | ||||
| Research and development expenses | 16,921 | 4,881 | 29,200 | 22,919 |
| Participation in research and development expenses | (2,855) | (823) | (12,411) | (11,055) |
| Research and development expenses, net | 14,066 | 4,058 | 16,789 | 11,864 |
| General, administrative and marketing expenses | 8,303 | 2,394 | 11,048 | 6,950 |
| Operating loss | 20,753 | 5,986 | 27,545 | 18,814 |
| Financial income | (253) | (74) | (93) | (215) |
| Financial expenses | 380 | 110 | 441 | 51 |
| Financial expenses (income), net | 127 | 36 | 348 | (164) |
| Comprehensive loss | ₪ 20,880 | $ 6,022 | ₪ 27,893 | ₪ 18,650 |
| Basic and diluted loss per ordinary share (NIS/USD) | (per share) | ₪ 0.16 | $ 0.05 | ₪ 0.28 | ₪ 0.22 |
| Weighted average ordinary shares outstanding | 133,187,048 | 133,187,048 | 100,624,945 | 84,672,767 |
| X | ||||||||||
- Definition The net amount of expenditure directly attributable to research or development activities. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share] Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of costs associated with financing activities of the entity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of income associated with interest and other financing activities of the entity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of income or cost associated with interest and other financing activities of the entity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue] Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The profit (loss) from operating activities of the entity. [Refer: Profit (loss)] Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The amount of expenditure directly attributable to research or development activities, recognised in profit or loss. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of expense relating to selling, general and administrative activities of the entity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of transfers of research and development from the entity in related party transactions. [Refer: Related parties [member]] Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|